Thermo Fisher Scientific Inc. (TMO) recently announced a partnership with the National Cancer Institute ("NCI") for the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. Under the trial, patients' bone marrow and blood will be tested for certain genetic biomarkers using Thermo Fisher's next-generation sequencing ("NGS") technology. With this, clinical sites can quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mut ...

Investors with an interest in Medical - Instruments stocks have likely encountered both Thermo Fisher Scientific (TMO) and Idexx Laboratories (IDXX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. TMO currently has a forward P/E ratio of 24.80, while IDXX has a forward P/E of ...

文章核心观点 - 公司在台湾开设首个电子显微镜演示中心NanoPort,旨在成为该地区的研发合作伙伴 [1][2][3] - 该中心将为客户提供电子显微镜专家和最新技术,支持基础研究和提高客户的生产效率 [4] - 电子显微镜市场预计将从2024年的51.3亿美元增长至2032年的102.2亿美元,年复合增长率为8% [5][6] 其他重要发展 - 公司推出生物基薄膜以减少疗法制造对气候的影响,并推出新型质谱仪 [7] - 公司在欧盟开设新的临床和商业超低温设施,扩大欧洲临床试验网络 [8] - 公司推出新一代血液基因分型解决方案 [9] 财务表现 - 公司股价今年迄今上涨0.2%,低于行业3.2%的增幅 [10] - 公司目前评级为买入评级 [11] - 同行业中Hims & Hers Health、Medpace和Haemonetics表现良好 [12][13][14][15][16][17][18]

A few of its recent strategic acquisitions that are likely to drive future growth include its plan to acquire Olink Holdings for $26.00 per common share in cash, which was announced in October. The acquisition is expected to enhance Thermo Fisher's capabilities in the high-growth proteomics market with the addition of highly differentiated solutions. Through the acquisition, the company expects to deliver $125 million in adjusted operating income synergies in the fifth year, driven by revenue synergies and ...

The new 65,000-square-foot space in Covington, KY, will expand the company's sample management and biorepository operations. The latest development will be in addition to its existing site in nearby Highland Heights. More on the News Thermo Fisher Scientific Inc. (TMO) recently announced the expansion of its central laboratory operations in Kentucky under its PPD clinical research business. The latest addition will help TMO to accelerate pharmaceutical and biotech customers' delivery of safe, effective medi ...

Thermo Fisher Scientific (TMO) recently unveiled the PlasmidPro Maxi Processor (PlasmidPro), its latest addition to the Thermo Scientific KingFisher instrument portfolio. The solution has a comprehensive range of key features that sets it apart as the only fully automated maxi-scale plasmid DNA (pDNA) purification system. Image Source: Zacks Investment Research Thermo Fisher is addressing the rapidly growing demand for plasmid DNA purification for emerging therapies with a new 'press and go' solution to spe ...

Thermo Fisher Scientific Inc. (TMO) has announced a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, WI, under its PPD clinical research business. The addition of a 72,500-square-foot building is likely to improve the company's clinical development and laboratory services by expanding the site's chemistry, manufacturing and control (CMC) analytical capabilities. This, in turn, should help its customers provide high quality and safety standards for patient ...

Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet global vaccine manufacturing requirements. Additionally, the pharma services business has been providing pharma and biotech customers with the services they need to develop and produce vaccines and therapies globally. Thermo Fisher's business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augmen ...

Thermo Fisher Scientific (TMO) recently introduced the Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators to support the future implementation of workflow automation in cell therapy production. These first-of-their-kind CO2 incubators are designed for integration into automated and modular laboratories. The latest development from Thermo Fisher represents the most advanced incubators in the VIOS portfolio. The company's VIOS family of incubators is known for optimal cell growth conditions and minimal c ...

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments The report analyzes all pipeline products in development for the company Thermo Fisher Scientific Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) The report covers detailed informatio ...